{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-031291","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.971493+00:00","generated_at":"2026-06-08T06:24:45.429230+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vistagen reports Q2 net loss $6.6M; fasedienol PALISADE-2 positive; cash $37.6M + $93.5M offering","bullets":["Net loss $6.6M for Q2 end Sep 30, 2023 vs $17.5M YoY; R&D expense decreased to $3.9M.","Cash $37.6M at Sep 30; raised $93.5M net from public offering plus $1.5M from Fuji Pharma.","Fasedienol PALISADE-2 Phase 3 met primary and secondary endpoints; PALISADE-3 and -4 planned 2024; NDA target 1H 2026.","Itruvone Phase 2B for MDD and PH80 Phase 2B for hot flashes expected 2H 2024; PH80 positive Phase 2A in PMDD."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-031291","json":"https://secwatch.observer/filing/0001437749-23-031291.json","markdown":"https://secwatch.observer/filing/0001437749-23-031291.md","text":"https://secwatch.observer/filing/0001437749-23-031291.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923031291/0001437749-23-031291-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923031291/vtgn20231109_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:24:45.429230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"301c8e9d05dbf88f2da7fece17592e57dd87a091","claim":"Vistagen Therapeutics, Inc. reported financial results for fiscal year 2024 second quarter ended September 30, 2023.","evidence_excerpt":"On November 9, 2023, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release to announce the Company’s financial results for its fiscal year 2024 second quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923031291/0001437749-23-031291-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2024 second quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}